DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Recruiting
LOCATIONS 1
University of California San Diego, La Jolla, California, United States|University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|NorthShore University Health System/Kellogg Cancer Center, Evanston, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massaschusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Morristown Medical/Atlantic Health, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Penn State Cancer Institute, Hershey, Pennsylvania, United States|Abramson Cancer Cener at Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Wyong Hospital, Hamlyn Terrace, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|Northern Cancer Institute (GenesisCare), Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Townsville University Hospital, Douglas, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Monash Health, Clayton, Victoria, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Epworth HealthCare - Richmond, Richmond, Victoria, Australia|Sunshine Hospital (Western Health), Saint Albans, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Sir Charles Gairdner Hospital (SCGH), Nedlands, Western Australia, Australia|Auckland City Hospital, Grafton, Auckland, New Zealand
Interventional
Drug: Durvalumab|Drug: Standard Chemotherapy|Drug: Ipilimumab and Nivolumab
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy combination (ipilimumab and nivolumab).
Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma.
The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.